Introduction and Background
• GAS is an "individualised" measure based on achievement of goals that are personal to each patient • This may overcome weaknesses of traditional scales which assess a standardised set of questions, regardless of the relevance of specific items to each individual patient
Use and Applicability
• The GAS was first developed in 1968 1 • It has been widely used, particularly in rehabilitation medicine (e.g. spasticity associated with stroke or cerebral palsy 2, 3 ). It has also been used in neuropsychiatric disorders e.g. dementia in Alzheimer's disease (AD) 4 and Parkinson's disease 5
• GAS scores are sensitive to treatment, may be more responsive than other patient-centred measures (e.g. heath-related quality of life, HRQoL) and may measure goals not reflected in standardised measures 6, 7 • GAS has been increasingly used in large Phase III 2 and IIIB/IV 3 studies, mainly as a secondary but also as a primary endpoint 3, 4 Psychometric Properties/Validity
• GAS has been shown to have high reliability, excellent responsiveness and variable validity across a variety of diseases 8
Operationalisation
The process follows these basic steps (Table 1 & Figure 1 ): 1. A patient's problems are assessed and goals for each defined (minimum 3; maximum 5-6) e.g. improve walking distance 2. For each goal, a GAS and an achievable "expected" outcome is agreed e.g. walking up the stairs unaided 3. GAS levels are defined for each point on, typically, a 5-point scale (Table 2 shows example GAS levels and descriptors) a. Expected outcomes often = 0 b. Baseline often = -2 (may be -1 or 0 depending whether deterioration expected e.g. AD) c. Goals must be relevant, observable, measurable, consistent with study design and treatment sensitive 4. A standardized statistical formula provides a measure of overall goal attainment most commonly expressed using a T-score 1 Little used in pharmacological intervention studies Independent GAS assessors may be required for blinded trials but will not be familiar with patient's usual attainment; may also require "control" GAS i.e. goals not affected by treatment
Unresolved statistical issues around single overall score and use of T score. Some believe ordinal nature of data requires use of non-parametric statistics 8 Attained goals for each of the relevant problem areas are then assessed against the predetermined personalised GAS levels e.g. a 'bit better' outcome on problem area I. would result in a score of '2'
Personalised GAS levels 
Benefits and Limitations
• The relative benefits and limitations of GAS are detailed in Table 3 . Additionally, some researchers argue that the GAS should not be a primary endpoint but should complement, rather than replace, standardised measures 6
Conclusion
• In capturing those outcomes relevant to each individual patient, GAS may have a more prominent role in support of claims in product labelling and HTA value assessment
Goal Attainment Scale (GAS) captures outcomes relevant to individual patients and provides "realworld" outcome measurement. This poster describes the background to its use, its operationalisation, strengths and limitations.
Traditional outcome measures assess a standardised set of questions regardless of their relevance to each patient. GAS overcomes these weaknesses because it is an individualised assessment based on achievement of goals which are personal to each patient. Despite it's widely cited use in academic literature and good psychometric properties it is rarely used in drug intervention studies. Operationalisation of GAS varies but follows these basic steps:
1. The patient's specific problem areas are assessed and goals for each defined 2. A GAS for each goal is created and an "expected outcome" for each agreed 3. Goal attainment levels are defined for each point on, typically, a 5-point scale (expected outcomes are usually scored 0; baseline is often -2, but may be -1 or 0 depending on potential for deterioration). Each level must be carefully described in a way that is relevant, observable, measurable and consistent with study design. Published standardised goals are available 4. A standardised statistical formula provides overall goal attainment Benefits include: ease of use; relevant goals; no redundant items; assessment of multiple domains; is quantifiable and applicable across different conditions and severities; potentially more sensitive measure than traditional scales. Limitations include: potential for bias; need for appropriate goal selection and outcome prediction; observable changes may differ from pre-defined outcomes; time consuming; may require independent GAS assessors for blinded trials; may require "control" goals not affected by treatment; statistical issues around single overall score. In capturing those outcomes relevant to each individual patient, GAS has potential use in supporting product labelling claims and value assessment of a medicine by HTA and payers.
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